The meeting point of the stomach and esophagus, the so-called gastro-esophageal junction, is a region of the human body that ...

if the site is at the level of the esophagogastric junction, a laparotomy is preferable, and the stomach can be used to reinforce the repair. If the damage to the esophagus is too extensive to ...

A phase I/II clinical trial of preoperative docetaxel/oxaliplatin/S-1 (DOS) combination therapy for esophagogastric junction adenocarcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding needs. Click for my LPTX stock update.

“Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver ...

Thoracoabdominal esophagectomy was performed for esophageal tumors and for esophagogastric junction tumors extending ... the construction and pull-up of a gastric conduit. Regional lymphadenectomy ...

Transcriptomic features of Epstein-Barr virus-associated gastric cancer based on PD-L1 status. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric cancer. Read more here.